Patients treated with monoclonal antibodies during COVID-19 delta surge had low rates of severe disease, study finds
A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to researchers.
Read Original Article: Patients treated with monoclonal antibodies during COVID-19 delta surge had low rates of severe disease, study finds »
